FHL2 is a novel target in pulmonary arterial hypertension

被引：0
|
作者：
Nadeem, C. [1 ]
Abbas, A. L. C. [1 ]
Verhoeven, D. T. B. [1 ]
Willems, L. [2 ]
Goumans, M. J. [2 ]
Kurakula, K. [1 ]
机构：
[1] Vrije Univ Med Ctr VUMC, Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
CARDIOVASCULAR RESEARCH | 2024年 / 120卷
关键词：
D O I：
10.1093/cvr/cvae088.185
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
cvae088.18
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phosphodiesterase-9 as a novel target to treat pulmonary arterial hypertension?
    Zhang, L.
    Bouadjel, K.
    Wang, L.
    Mercier, O.
    Antigny, F.
    Perros, F.
    Fischmeister, R.
    Leblais, V.
    Manoury, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 30 - 30
  • [12] DNA-PKcs: A Novel Therapeutic Target in Pulmonary Arterial Hypertension
    Yamamoto, Keiko
    Yokokawa, Tetsuro
    Lemay, Sarah-Eve
    Bourgeois, Alice
    Shimauchi, Tsukasa
    Shimauchi, Kana
    Nadeau, Valerie
    Salem, Mabrouka
    Bonnet, Sandra Breuils
    Potus, Francois
    Boucherat, Olivier
    Provencher, Steeve
    Bonnet, Sebastien
    CIRCULATION, 2022, 146
  • [13] The role of FHL2 in the dendritic cell migration
    Koenig, K.
    Diehl, L.
    Rommerscheidt-Fuss, U.
    Golletz, C.
    Quast, T.
    Kolanus, W.
    Knolle, P. A.
    Buettner, R.
    Heukamp, L. C.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 119 - 119
  • [14] CMYA5 is a novel interaction partner of FHL2 in cardiac myocytes
    Stathopoulou, Konstantina
    Schnittger, Josef
    Raabe, Janice
    Fleischer, Frederic
    Mangels, Nils
    Piasecki, Angelika
    Findlay, Jane
    Hartmann, Kristin
    Krasemann, Susanne
    Schlossarek, Saskia
    Uebeler, June
    Wixler, Viktor
    Blake, Derek J.
    Baillie, George S.
    Carrier, Lucie
    Ehler, Elisabeth
    Cuello, Friederike
    FEBS JOURNAL, 2022, 289 (15) : 4622 - 4645
  • [15] The role of FHL2 in wound healing and inflammation
    Wixler, Viktor
    FASEB JOURNAL, 2019, 33 (07): : 7799 - 7809
  • [16] FHL2 expression and variants in hypertrophic cardiomyopathy
    Felix W. Friedrich
    Silke Reischmann
    Aileen Schwalm
    Andreas Unger
    Deepak Ramanujam
    Julia Münch
    Oliver J. Müller
    Christian Hengstenberg
    Enrique Galve
    Philippe Charron
    Wolfgang A. Linke
    Stefan Engelhardt
    Monica Patten
    Pascale Richard
    Jolanda van der Velden
    Thomas Eschenhagen
    Richard Isnard
    Lucie Carrier
    Basic Research in Cardiology, 2014, 109
  • [17] FHL2 expression and variants in hypertrophic cardiomyopathy
    Friedrich, Felix W.
    Reischmann, Silke
    Schwalm, Aileen
    Unger, Andreas
    Ramanujam, Deepak
    Muench, Julia
    Mueller, Oliver J.
    Hengstenberg, Christian
    Galve, Enrique
    Charron, Philippe
    Linke, Wolfgang A.
    Engelhardt, Stefan
    Patten, Monica
    Richard, Pascale
    van der Velden, Jolanda
    Eschenhagen, Thomas
    Isnard, Richard
    Carrier, Lucie
    BASIC RESEARCH IN CARDIOLOGY, 2014, 109 (06)
  • [18] Mapping of FHL2 transcription activation domain
    Yan, JH
    Ye, QN
    Fang, Y
    Zhu, JH
    Huang, CF
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2003, 35 (07) : 643 - 648
  • [19] The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF
    Philippar, U
    Schratt, G
    Dieterich, C
    Müller, JM
    Galgóczy, P
    Engel, FB
    Keating, MT
    Gertler, F
    Schüle, R
    Vingron, M
    Nordheim, A
    MOLECULAR CELL, 2004, 16 (06) : 867 - 880
  • [20] PHOSPHODIESTERASE 2 IS A NOVEL THERAPEUTIC TARGET IN PULMONARY HYPERTENSION
    Hobbs, A.
    Bubb, K.
    Trinder, S.
    Baliga, R.
    MacAllister, R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 40 - 41
12345